Drug Trial Radar · NCT07111078
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Aug 27, 2025
Primary completion
Aug 18, 2027
Study completion Aug 18, 2027
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu. Some vaccines are combined with adjuvants. Adjuvants are special salts or fats that help vaccines work better. Researchers are looking for ways to make flu vaccines more effective. Objective: To test a new flu vaccine with and without a new adjuvant. Eligibility: Healthy adults aged 18 to 50. They must have had at least 1 flu vaccine since 2020. Design: Participants will have 12 clinic visits over 15 months. The vaccine is given as an injection into the muscle of the upper arm. Participants will be vaccinated during 2 visits spaced 4 months apart. Half will receive just the vaccine; half will receive the vaccine plus the adjuvant. They will be monitored for at least 30 minutes after each shot. Participants will keep a diary for 7 days after each shot. They check their temperature every day and record any symptoms. Participants will have 10 follow-up clinic visits plus 4 phone calls. They will have 4 to 10 tablespoons of blood drawn at each clinic visit. Fluid samples will be collected from their nose and mouth. They will be checked for any health changes. Participants may opt to undergo apheresis: Blood will be taken from the body through a needle inserted into a vein. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be returned to the body through a different needle.
Conditions
- Influenza Prevention
- Pandemic Influenza Prevention
Interventions
VRC-FLUMOS0122-00-VPBiological
The VRC-FLUMOS0122-00-VP (SteMos1) is composed of de novo engineered pentamer assembled with de novo engineered trimeric domains to an icosahedral core, projecting 20 HA stabilized stem trimers from four influenza A strains representing both Group 1 (H2, H5) and Group 2 (H7, H10) viruses.
ALFQOther
The ALFQ drug product is a sterile suspension that contains 240 mcg of monophosphoryl 3-deacyl Lipid A (3D-PHAD) and 120 mcg QS-21
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of 180 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine with ALFQ adjuvant administered as a 2-dose regimenTime frame: Though 52 weeks after the second vaccine administration
- Safety and tolerability of 60 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine with ALFQ adjuvant administered as a 2-dose regimenTime frame: Though 52 weeks after the second vaccine administration
- Safety and tolerability of 180 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine without ALFQ adjuvant administered as a 2-dose regimenTime frame: Though 52 weeks after the second vaccine administration
- Safety and tolerability of 60 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine without ALFQ adjuvant administered as a 2-dose regimenTime frame: Though 52 weeks after the second vaccine administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.